|
|
||||||||
|
|
|||||||||
|
|
General Clinical Specialties: EndocrinologyEndocrinology Posters |
1 Medical Diagnostics, GE Healthcare, Princeton, New Jersey; 2 Nuc Med, Mt Sinai Hosp, New York, New York; 3 Nuc Med, U Miami Hosp, Miami, Florida; 4 Radiology, Piedmont Hosp, Atlanta, Georgia
1028
Objectives: This study assessed the impact of SPECT on the interpretation of 123I-mIBG studies for the evaluation of patients (pts) with known or suspected pheochromocytoma and neuroblastoma.
Methods: In a prospective multicenter trial, 149 pts with known or suspected pheochromocytoma and 51 with known or suspected neuroblastoma underwent whole-body planar and chest/abdomen SPECT imaging 24 (± 6) hours following administration of 123I-mIBG, 10 mCi (370 MBq) for adults and 1-10 mCi (37-370 MBq) for children. 3 blinded readers examined planar images alone first, then perfomed a combined interpretation with planar plus SPECT. Consensus required at least 2 readers in agreement. Confirmation of disease was based upon histopathology, other imaging, catecholamine measurements, and clinical follow-up.
Results: 122 pts had active disease, 57 were judged without disease, and 21 were considered indeterminate based upon inadequate follow-up data. 123I-mIBG planar scintigraphy had a sensitivity (Se) of 81% (99/122) and specificity (Sp) of 79% (45/57). With SPECT, there was a modest increase in Se (86%; 105/122) with minimal change in Sp (77%; 44/57). SPECT changed the interpretations of 17 studies: negative to positive -12 (9 true-positive); positive to negative – 5 (2 true-negative). SPECT clarified findings on planar imaging in 38-46% and provided additional diagnostic value in 32-41% of pts.
Conclusions: While providing a small improvement in quantitative performance, 123I-mIBG SPECT assisted the readers interpretation in almost half the pts. The greatest impact of SPECT was to increase the number of positive studies, both true- and false-positive.
Research Support: GE Healthcare
| ||||||||||||||||||||||||||||||||||||||